Financial Impact of a Long-Acting Injectable Cabotegravir/Rilpivirine Program: A Real-World Experience.
- DOI
- 10.1093/cid/ciag537
- Published
- 2026 Sep 1
- Container
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1093/cid/ciag537,
title = {Financial Impact of a Long-Acting Injectable Cabotegravir/Rilpivirine Program: A Real-World Experience.},
author = {Havens JP and O'Neill J and Kubat M and Davis JM and Fadul N and Sunagawa SW and Bares SH},
year = {2026},
journal = {Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
doi = {10.1093/cid/ciag537},
url = {https://doi.org/10.1093/cid/ciag537}
}RIS
TY - JOUR TI - Financial Impact of a Long-Acting Injectable Cabotegravir/Rilpivirine Program: A Real-World Experience. AU - Havens JP AU - O'Neill J AU - Kubat M AU - Davis JM AU - Fadul N AU - Sunagawa SW AU - Bares SH PY - 2026 JO - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America DO - 10.1093/cid/ciag537 UR - https://doi.org/10.1093/cid/ciag537 ER -
APA
JP, H., J, O., M, K., JM, D., N, F., SW, S., & SH, B. (2026). Financial Impact of a Long-Acting Injectable Cabotegravir/Rilpivirine Program: A Real-World Experience.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. https://doi.org/10.1093/cid/ciag537
Source records
- pubmed · retrieved 2026-09-25T02:23:26.035Z